Amazon (AMZN): Takeaways From Online Pharmacy Call - Citi

January 22, 2018 7:44 AM EST
Get Alerts AMZN Hot Sheet
Price: $2,135.50 +2.57%

Rating Summary:
    55 Buy, 4 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 10 | Down: 13 | New: 20
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Citi analyst, Mark May, reiterated his Buy rating on shares of Amazon.com (NASDAQ: AMZN) after hosting a conference call for clients to discuss the emerging online pharmacy market with the CEO of privately-held PillPack (TJ Parker), the largest online pharmacy in the country.

Key takeaways:

1) The size of the market opportunity in the U.S. is ~$400bn, with ~80% of that market being particularly well suited for e-commerce given the prominence of recurring prescriptions for chronic illnesses.

2) Obtaining licenses in every state for e-commerce pharmacy operation is not intellectually challenging but takes 12-18 months from start to finish.

3) 30mm Americans take 5 or more medications, which represents more than $100bn of the $400bn in domestic prescription spend.

4) Logistics/distribution is one of the three key elements of pharmacy and Amazon can do this as well as any. Amazon’s primary challenge will be developing a front-end tool for the customer experience – making sure the right prescriptions are sent at the right time.

No change to the price target of $1,400.

For an analyst ratings summary and ratings history on Amazon.com click here. For more ratings news on Amazon.com click here.

Shares of Amazon.com closed at $1294.58 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Citi